Protara Therapeutics, Inc. (TARA)
NasdaqGM
Price as at 1 Oct 2026, 02:16 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Protara Therapeutics, Inc. trades at $3.05. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$11.85M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$4.71M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$2.68M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$2.10M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$960.7K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own TARA?
9 of the institutions we track reported a position in TARA in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its TARA data?
Fundamentals for TARA come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 02:16 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for TARA, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.